The Thoc1 Ribonucleoprotein as a Novel Biomarker for Prostate Cancer Treatment Assignment

Abstract

Active surveillance (AS) is an option for men with low risk prostate cancer in order to reduce over treatment, but few men choose it because current prognostic indicators are imperfect. The objectives of this research are to test whether pThoc1 can improve the assignment of prostate cancer patients to therapy. We have made significant progress on the goals articulated in the Statement of Work. IRB/HRPO approval has been obtained for construction and use of new TMAs (PI Mohler and Goodrich). The TMAs from PCaP have been obtained (PI Mohler and Goodrich). Pathology analysis of 1146 patient specimens and construction of TMAs are completed and the TMA sections were requested, pending immunostaining (PI Mohler). Optimization of TMA staining is complete and staining of PCaP TMAs initiated (PI Goodrich).

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2017
Accession Number
AD1042928

Entities

People

  • James L Mohler

Tags

DTIC Thesaurus Topics

  • African Americans
  • Biological Markers
  • Cancer
  • Cell Line
  • Construction
  • Department Of Defense
  • Diseases And Disorders
  • Genetic Variation
  • Health Services
  • Immunostaining
  • Medical Personnel
  • Neoplasms
  • Physicians
  • Prostate
  • Prostate Cancer
  • Tissues
  • Virtual Reality

Readers

  • Oncology and Biomarker-Based Cancer Detection.